Angiogenesis of lung cancer utilizes existing blood vessels rather than developing new vessels using signals from carcinogenesis

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1913-1916

  Uramoto, Hidetaka ^a   Yamada, Sohsuke ^b   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Angiogenesis; EGFR; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CANCER CELL; CARCINOGENESIS; ENDOTHELIUM CELL; EXON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LUNG CANCER; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ANGIOGENESIS; EGFR; LUNG CANCER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIUM, LYMPHATIC; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; YOUNG ADULT;

EID: 84878182622     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Ballas MS and Chachoua A: Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 4:43-58, 2011.
3. Evans T: Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. Anticancer Res 32: 4629-4638, 2012.
4. Gomes FG, Nedel F, Alves AM, Nör JE and Tarquinio SB: Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 92: 101-107, 2013.
5. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
6. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis/ micrometastasis and adhesion related molecules in resected stage I NSCLC. Lung Cancer 70: 320-328, 2010.
7. Pallis AG and Syrigos KN: Targeting tumor neovasculature in non-small- cell lung cancer. Crit Rev Oncol Hematol in press
8. Chung AS, Kowanetz M, Wu X, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F and Ferrara N: Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 227: 404-416, 2012.
9. Onimaru M and Yonemitsu Y: Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Front Biosci 3: 216-225, 2011.
10. Gottfried E, Kreutz M, Haffner S, Holler E, Iacobelli M, Andreesen R and Eissner G: Differentiation of human tumour-associated dendritic cells into endothelial-like cells: An alternative pathway of tumour angiogenesis. Scand J Immunol 65: 329-335, 2007. (Pubitemid 46481100)
11. Jung YD, Ahmad SA, Liu W, Reinmuth N, Parikh A, Stoeltzing O, Fan F and Ellis LM: The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 12: 105-112, 2002. (Pubitemid 34680739)
12. Kawahara A, Yamamoto C, Nakashima K, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T and Ono M: Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16: 3163-3170, 2010.
13. Yatabe Y, Kosaka T, Takahashi T and Mitsudomi T: EGFRmutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29: 633-639, 2005. (Pubitemid 40577873)
14. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki Y, So T, Nakata S, Morita M and Yasumoto K: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94: 896-903, 2006.
15. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T and Yasumoto K: Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol 5: 1136-1142, 2010.
16. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
17. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-RAS, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
18. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA and Smit EF: Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of antiangiogenic drugs. Cancer Cell 21: 82-91, 2012.
19. Ricciardi S, Tomao S and de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10: 28-35, 2009.